Science news

<<  return


NORSTENT: Drug-Eluting, Bare-Metal Coronary Stents Similar for Survival

The largest trial to compare contemporary bare-metal stents with modern drug-eluting stents (DES) for PCI found that patients who received the DES did not gain an advantage for the primary end point of MI-free survival at 6 years compared with patients who received the bare-metal stent.

However, in the Norwegian Coronary Stent Trial (NORSTENT) trial with >9000 patients, those treated with DES had a significantly reduced risk of repeat revascularization of any kind and of target-lesion revascularization (TLR).

The trial showed that patients treated with DES do not live longer or better than patients treated with a bare-metal stent, and the long-term benefit of a contemporary DES over a bare-metal stent was somewhat less than expected.

The results of the trial were presented at the European Society of Cardiology (ESC) 2016 Congress; the study article simultaneously was published in the New England Journal of Medicine.